Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from ProMIS Neurosciences ( (PMN) ) is now available.
On May 20, 2026, ProMIS Neurosciences held its Annual Meeting, at which shareholders representing approximately 53.1% of outstanding common shares were present or represented by proxy. Investors elected seven directors to serve until the 2027 annual meeting, with each nominee receiving a clear majority of votes despite a modest level of withheld votes and broker non-votes.
Shareholders also ratified the appointment of Baker Tilly US, LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with overwhelming support and minimal opposition. In addition, they approved an amendment to the 2025 Stock Option and Incentive Plan to increase the share reserve by 900,000 common shares, a move that enhances the company’s flexibility to grant equity-based compensation and could affect future shareholder dilution while supporting talent retention and alignment with long-term strategic goals.
The most recent analyst rating on (PMN) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on ProMIS Neurosciences stock, see the PMN Stock Forecast page.
Spark’s Take on PMN Stock
According to Spark, TipRanks’ AI Analyst, PMN is a Neutral.
The score is primarily pressured by weak financial performance (no revenue, large losses, and continued cash burn). Technicals also detract given the stock is trading below key moving averages with negative MACD. Valuation provides limited support because earnings are negative and no dividend yield is available.
To see Spark’s full report on PMN stock, click here.
More about ProMIS Neurosciences
ProMIS Neurosciences operates in the life sciences sector, focusing on the development of therapeutics for neurodegenerative diseases using a proprietary, target-specific antibody platform. The company’s strategy centers on advancing its pipeline of treatments aimed at conditions such as Alzheimer’s disease, positioning itself within the biotech segment targeting high-unmet-need neurological indications.
Average Trading Volume: 44,454
Technical Sentiment Signal: Strong Sell
Current Market Cap: $22.46M
Learn more about PMN stock on TipRanks’ Stock Analysis page.